Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia

Overview of attention for article published in Journal of Hematology & Oncology, April 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

So far, Altmetric has seen 21 X posts from 20 X users, with an upper bound of 26,807 followers.

RT @skyhigh0707: 移植後再発T-ALLに対し、ドナー由来CD7 CAR-T細胞を投与し、奏効率95％、CR率85％だったという報告😆前の移植ドナー由来CART投与後は移植をしていませんが、新しいドナー由来の場合は、CART投与後同じドナーから移植して長期寛解を得…

#CART CD7 for T cell ALL, allogeneic CAR, long term follow up https://t.co/BxAWow1LUj

RT @CARTTherapy: Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia https://t…

RT @CARTTherapy: Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia https://t…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 17 additional X posts.